Neotherapuetics possibly has a breakthrough drug - NEOT Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT

NEOT 1.919

+4.3%

Jan 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LadyNada who wrote (31)	9/14/1999 5:18:00 PM
From: LadyNada	Read Replies (1) of 204

Roche could use a new partner like NEOT Roche halts Alzheimer's drug Reuters Story - September 14, 1999 04:34 Jump to first matched term ZURICH, Sept 14 (Reuters) - Roche Holding AG said on Tuesday it had stopped developing its Tempium brand drug for treating Alzheimer's disease after liver problems developed in some patients during clinical trials. A spokesman did not give any potential sales figures for the drug, but said Roche had other compunds for treating the disease in late-stage research and was evaluating whether to start clinical trials with one or more. In its interim results statement last month, Roche described Tempium, or Lazabemide, as showing great potential. It is another setback for Roche, which had to pull its heart drug Posicor and sharply restrict sales of its Parkinson's disease drug Tasmar last year amid concerns about side effects. "Development (of Lazabemide) was discontinued due to recent observations in a few patients of abnormal liver tests," the spokesman said. "Alzheimer's disease is a huge unmet medical need, and we are fully committed to that research area. Unfortunately, Lazabemide did not live up to its potential. But we have additional compounds in late-stage research and we are currently evaluating whether to go into clinical trials with additional compounds." He declined to say how long it might take to get such a compound on to the market. Industry analysts say this process usually takes three to five years. Roche certificates were down 165 Swiss francs to 17,995 around 0835 GMT in a firmer Swiss market

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next